Primary non-small cell lung cancer response upon treatment with denosumab

Lung Cancer

Volumn 82, Issue 3, 2013, Pages 506-508

  Curioni Fontecedro, A ^a   Husmann, L ^a   Soldini, D ^a   Stahel, R A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ALK; Crizotinib; Denosumab; NF kB; Non small cell lung cancer; RANK; RANKL

Indexed keywords

CISPLATIN; CRIZOTINIB; DENOSUMAB; FLUORODEOXYGLUCOSE; PEMETREXED;

ADULT; ARTICLE; BONE LESION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE SEVERITY; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; TUMOR VOLUME;

ALK; CRIZOTINIB; DENOSUMAB; NF-KB; NON SMALL CELL LUNG CANCER; RANK; RANKL;

ANTIBODIES, MONOCLONAL, HUMANIZED; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; COUGH; DNA MUTATIONAL ANALYSIS; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; RANK LIGAND; RECEPTOR PROTEIN-TYROSINE KINASES; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84887610043     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.030     Document Type: Article

References (6)

1. Henry D.H., Costa L., Goldwasser F., Hirsh V., Hungria V., Prausova J., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
2. Scagliotti G.V., Hirsh V., Siena S., Henry D.H., Woll P.J., Manegold C., et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012, 7:1823-1829.
3. Hoffmann A., Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006, 210:171-186.
4. Peters S., Meylan E. Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer. Curr Opin Oncol 2013, 25:137-144.
5. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008, 68:3389-3395.
6. Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaia M., Hanafusa H., et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999, 4:1041-1049.